AzTrials
AzTrials

MeningiomaPhase 2NCT06012929

A Study of ONC201 for Refractory Meningioma

A Phase 2 study testing ONC201 in people with Meningioma and Refractory Meningioma, run by University of Nebraska.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn about treatment for a type of brain tumor called a meningioma. This study will enroll two groups of people. One group will be for people who will receive surgery to remove their brain tumor. Read more about this study

Who is it for?
Ages 19 years and older
What is being tested?
ONC201
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
Dec 2026to Apr 2027
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • For both study arms:
  • Brain imaging demonstrating a meningioma for which resection has been recommended (Arm I) or any subject with pathologically proven meningioma without reasonable surgical options for complete resection, or reasonable radiation therapy options, determined by neurosurgery and radiation oncology opinions (Arm II)
  • Age > 18 years old at time of study entry (consent) or adult male or female (For Nebraska, age of consent is ≥19 years old)
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Adequate organ and marrow function as defined below:
  • Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to treatment (cycle 1 day 1, C1D1)
Show all 22Show fewer
  • Hemoglobin >8.0 mg/dL without red blood cell transfusion ≤ 3 days prior to C1D1
  • Total serum bilirubin <1.5 X upper limit of normal (ULN), except in cases of Gilbert's disease
  • Aspartate aminotransferase (AST) (SGOT)/Alanine transaminase (ALT) (SGPT) ≤2 X ULN secondary to tumor
  • Serum creatinine ≤ 1.5 X ULN (OR creatinine clearance ≥ 60 mL/min/1.73 m2)
  • Ability to understand and the willingness to sign a written informed consent document.
  • Female subjects must be surgically sterile or be postmenopausal, or must agree to use effective contraception while on ONC201 and for at least 90 days after completion of treatment. Male subjects must be surgically sterile or must agree to use effective contraception while on ONC201 and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.
  • Any number of prior medical therapies is allowed but not required.
  • Multifocal disease is allowed.
  • Subjects with history of neurofibromatosis may have other stable central nervous system (CNS) tumors (schwannoma, acoustic neuroma or ependymoma) if lesions have been stable for 6 months.
  • For Arm II only:
  • Progression by Macdonald criteria: increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area). Progressive disease must based on scans done within 12 months or fewer of each other.
  • Subject must have no reasonable surgical or radiation therapy options, determined by neurosurgery and radiation oncology opinions.
  • Evidence of progressive disease at least 24 weeks after completion of radiation (external beam, interstitial brachytherapy, or radiosurgery).
  • Subject who elected to have partial tumor resection after confirmed progressive disease may still be considered, but radiographic measurable residual tumor(s) are required at baseline
  • Stable or decreasing steroid dose for two weeks.
  • Archival tissue must be available for correlative studies-a minimum of ten slides to be eligible, with up to 20 slides requested.

Who cannot join

  • Participation in another clinical study with an investigational product during the last 28 days.
  • Active chemotherapy, including other investigational agents within 28 days of study treatment.
  • Craniotomy or other major surgery within 28 days of registration.
  • Evidence of metastatic meningiomas (as defined by extracranial meningiomas).
  • Known active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV).
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
Show all 12Show fewer
  • Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, or cerebrovascular accident. Subjects planning to continue on study after progression with the addition of bevacizumab cannot have uncontrolled hypertension, nephrotic syndrome, or had a history of intracranial bleeding or GI hemorrhage in the last 6 months.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the subject inappropriate for entry into the study.
  • Concomitant treatment with strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors or inducers. Subject must discontinue the drug for 14 days prior to registration.
  • Prolongation of QT/corrected QT interval by Fridericia (QT/QTcF) interval (QTc interval >480 milliseconds) using Frederica's QT correction formula on two ECGs separated by at least 48 hours.
  • A history of Torsades de pointes or heart failure, hypokalemia, or family history of prolonged QT Syndrome.
  • Concomitant use of medication(s) known to prolong the QT/QTc interval.

About this study

Official title: A Pilot Study, Open-Label Study of ONC201 for Refractory Meningioma

The goal of this clinical trial is to learn about treatment for a type of brain tumor called a meningioma. This study will enroll two groups of people. One group will be for people who will receive surgery to remove their brain tumor. The other group will be for people who have previously received treatment for their brain tumor but do not have any other available options for treatment.

The primary goals of this study are:

  1. To measure how much of the study drug is present in tumor tissue taken from patients during surgery to remove their brain tumor
  2. To measure the length of time between a study participant's first dose of study treatment until the time when their brain tumor gets worse or their death
Read the detailed description

Patients will be enrolled in one of two arms, either the presurgical arm or the treatment arm. Patients who will be undergoing surgery to remove their meningioma will be enrolled to Arm I. Patients who have previously received treatment for their meningioma but have exhausted all reasonable treatment options will be enrolled to Arm II.

All patients will take the study medication, ONC201, by mouth once per week at a dose of 625 mg.

  • Arm I patients will receive two doses of ONC201 prior to surgery, with the second dose occurring approximately 24 hours before surgery.
  • Arm II patients will receive one 625 mg dose of ONC201 per week until disease progression or intolerable toxicity.

Primary Objectives

  1. To evaluate the concentration of ONC201 in resected meningioma tissue (Arm I)
  2. To measure progression-free survival in patients receiving ONC201 who have exhausted all other reasonable treatment options (Arm II)

Secondary Objectives

  1. To evaluate tumor response via radiographic imaging following treatment with ONC201
  2. To correlate dopamine receptor D2 (DRD2) expression with tumor response to treatment via molecular studies performed on archival and fresh tissue
  3. To determine overall survival
  4. To determine the efficacy of adding bevacizumab to ONC201 in patients who have progressed on ONC201 alone
Being tested
ONC201
Medical subject headings
Meningioma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ONC201Drug

    Also called dordaviprone

    ONC201 is an oral medication given once per week

Study groups in NCT06012929
Study groupRoleWhat they receive
Arm I - PresurgicalExperimentalParticipants who will be undergoing surgery to remove their meningioma will receive two doses of ONC201 prior to their surgery. ONC201 is taken by mouth at 625 mg per dose. ONC201 will be taken once per week with the second dose taken approximately 24 hours prior to surgery.
Receives: Drug: ONC201
Arm II - ONC201 treatment onlyExperimentalParticipants will receive one dose of ONC201 per week until progression. ONC201 is taken by mouth at 625 mg per dose.
Receives: Drug: ONC201

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of ONC201 concentration in resected meningioma tissue

    Tumor tissue will be collected from Arm I participants at the time of surgical resection. The samples will be analyzed for the concentration of ONC201 in the tissue.

    Measured: Up to 12 months

  2. Evaluation of progression-free survival (PFS)

    PFS at 6 months will be evaluated in participants assigned to Arm II. PFS is defined as the time from the start of study treatment to the time of disease progression or death. Participants without progression and who are alive at the time of last follow-up will be censored.

    Measured: Up to 18 months

Secondary outcomes (3)

  1. Evaluation of tumor response from ONC201 on imaging

    Tumor response from ONC201 on imaging will be measured by contrast-enhanced brain MRI completed every 12 weeks. Response will be determined using Macdonald criteria. The Macdonald criteria evaluates the status of lesions present on baseline imaging, the appearance of new lesions, corticosteroid use, and clinical status to determine the appropriate response category. The possible response categories include complete response, partial response, stable disease, and progressive disease.

    Measured: Up to 24 months

  2. Correlation of DRD2 expression with tumor response

    Archival formalin-fixed paraffin embedded (FFPE) tumor tissue samples will be collected from Arm II participants at the time of study enrollment. The tissue samples will be tested for the level of DRD2 expression. The mechanism of action for the study medication, ONC201, is the through the inhibition of DRD2 receptors, a type of dopamine receptor. DRD2 expression will subsequently be correlated with best response and compared by response categories with Kruskal-Wallis test or Wilcoxon rank sum test, depending on the number of response levels.

    Measured: Up to 12 months

  3. Evaluation of the efficacy of adding bevacizumab to ONC201 following disease progression

    Tumor response from ONC201 with bevacizumab on imaging will be measured by contrast-enhanced brain MRI completed every 12 weeks. Response will be determined using Macdonald criteria. The Macdonald criteria evaluates the status of lesions present on baseline imaging, the appearance of new lesions, corticosteroid use, and clinical status to determine the appropriate response category. The possible response categories include complete response, partial response, stable disease, and progressive disease.

    Measured: Up to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Aug 2023
  2. Study startDec 2026 (estimated)
  3. Primary completionApr 2027 (estimated)
  4. Study completionApr 2027 (estimated)

Why it stopped: Protocol not moving forward.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06012929
Sponsor's protocol ID
0137-24-FB
Status last verified
Jan 2025
First submitted
3 Aug 2023
Last updated
26 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ONC201 in people with Meningioma and Refractory Meningioma, run by University of Nebraska.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 22 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of ONC201 concentration in resected meningioma tissue (time frame: Up to 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06012929.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in